Ocular and rare disease gene therapy company. Lead program, ADVM-022, currently in a Phase 1 study in wAMD. Preclinical programs in A1AT deficiency and HAE. Collaborations in place with Regeneron and Editas.
Phase l or ll, Pre-Clinical Stage
Ophthalmology, Rare Disease
1035 O'Brien Drive
Menlo Park, CA 94025
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by